Exchange Announcement • 14 Oct 2026 15:00
Nxera Pharma Enters Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Exchange Announcement • 03 Sep 2026 14:30
Nxera Pharma To Receive $8.6 Million Milestone Payment From Centessa Pharmaceuticals Following Late-Stage Development Progress
Exchange Announcement • 26 Aug 2026 15:30
Nxera Pharma’S Partner Neurocrine Biosciences Receives Ind Acceptance From The Fda For Phase 2 Study Of Nbi-1117567 For Alzheimer'S Cognition
Exchange Announcement • 30 Jun 2026 14:30
Nxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases
Exchange Announcement • 10 Jun 2026 14:30